Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 1;7(1):202.
doi: 10.1186/s40425-019-0686-x.

State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019

Richard Lemal  1   2 , Olivier Tournilhac  3
Affiliations
Review

State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019

Richard Lemal et al. J Immunother Cancer. .

Abstract

Experience in the use of CAR T cells to treat CLL is limited, but safety and efficacy data are encouraging, suggesting that it may be possible to use CAR T cells in populations of CLL patients with particularly unfavorable prognoses. Mechanisms intrinsic to the pathophysiology of CLL undoubtedly explain the efficacy reported based on limited data for the first few series, and underlie the rationale of successive modulations in lymphodepletion schemes, transgene constructs, and, finally, the therapeutic association of CAR T cells with ibrutinib, which appears to be particularly promising. This review describes the published results and expected developments.

Keywords: CAR T cells; CLL; Ibrutinib.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92(9):946–965. doi: 10.1002/ajh.24826. - DOI - PubMed
    1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760. doi: 10.1182/blood-2017-09-806398. - DOI - PubMed
    1. Buske C, Hutchings M, Ladetto M, Goede V, Mey U, Soubeyran P, et al. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(3):544–562. doi: 10.1093/annonc/mdx413. - DOI - PubMed
    1. Fischer K, Hallek M. Optimizing frontline therapy of CLL based on clinical and biological factors. Hematol Am Soc Hematol Educ Program. 2017;2017(1):338–345. doi: 10.1182/asheducation-2017.1.338. - DOI - PMC - PubMed
    1. Tournilhac O, Garff-Tavernier ML, Tabrizi R, Nguyen-Quoc S, Legrand-Izadifar F, Combes P, et al. RIC allogeneic stem cell transplantation for high risk CLL followed by preemptive MRD-based immunointervention - final results from the phase II ICLL03 Ricac-Pmm trial (FILO - SFGM-TC French intergroup) Blood. 2017;130(Suppl 1):4599.

MeSH terms

LinkOut - more resources